BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical is a leading rare-disease biotech — Voxzogo, Vimizim, Naglazyme, Aldurazyme, plus the recently-acquired Amicus Therapeutics franchise — building a diversified rare-disease commercial platform. The recent M&A cadence is aggressive and specifically targeted at expanding the rare-bone-disease franchise.

What just happened:

• The Alesta Therapeutics acquisition was announced August 18: $275M upfront (cash-free, debt-free basis) for a Dutch private rare-disease company developing oral small-molecule therapies — specifically ALE1, a potential first oral therapy for Hypophosphatasia, which fits the rare-bone-disease franchise BioMarin is building.
• A separate $490M rare-bone-disease deal was announced in the coverage — combined with the Alesta transaction, BioMarin has committed nearly $800M to rare-bone-disease M&A in the last month, a specific strategic focus.
• The Amicus Therapeutics acquisition closed April 27 with an 8-K/A on July 13 providing the required audited financial statements plus pro forma financial information — standard post-merger paperwork indicating the integration is proceeding on schedule.
• Revenue growth is meaningful: Q1 revenue was $990M (+19.9% YoY) and the prior quarter was $766M (+2.8%) — the sequential acceleration reflects both the Amicus contribution and the organic Voxzogo/Vimizim ramps.

The bull path is the Oct 26 Q3 print continuing revenue-growth acceleration plus specific commentary on Amicus integration synergies and Alesta-deal timing, at which point $75+ opens; the bear read is a specific rare-disease-competitive readout that dents Voxzogo peak-sales math, or a specific rare-bone-disease pipeline setback that questions the M&A strategy, in which case the current 75% of range gives back a chunk.